Pharmaceutical

EMA CHMP supports CStone’s sugemalimab for metastatic NSCLC

EMA's CHMP has recommended the approval of CStone's sugemalimab for the first-line treatment of metastatic non-small cell lung cancer.

Jun 4, 2024 - 04:00
EMA CHMP supports CStone’s sugemalimab for metastatic NSCLC
EMA's CHMP has recommended the approval of CStone's sugemalimab for the first-line treatment of metastatic non-small cell lung cancer.
Read the original article

Tags:

Previous Article

Inline, real-time PAT tool is a game-changer for pharma granulation sector

Next Article

FDA approves Moderna’s RSV vaccine mRESVIA

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Type 2 diabetes prevention programs can work at large scale, study finds

Type 2 diabetes prevention programs can work at large s...

Nov 15, 2023

Evotec shuts down gene therapy business in light of Q1 2024 loss 

Evotec shuts down gene therapy business in light of Q1 ...

May 23, 2024

STAT+: Pharmalittle: Deadline looms for drugmakers to negotiate with Medicare; GOP senator probes 340B program at two hospitals

STAT+: Pharmalittle: Deadline looms for drugmakers to n...

Sep 30, 2023